- Report
- February 2023
- 110 Pages
Global
From €3008EUR$3,160USD£2,580GBP
€3761EUR$3,950USD£3,226GBP
- Report
- May 2023
- 138 Pages
Global
From €2379EUR$2,499USD£2,041GBP
- Report
- August 2020
Global
From €5036EUR$5,290USD£4,320GBP
- Report
- June 2022
- 145 Pages
Global
From €2379EUR$2,499USD£2,041GBP
- Clinical Trials
- May 2021
Global
From €1904EUR$2,000USD£1,633GBP
€2380EUR$2,500USD£2,042GBP
- Report
- February 2022
- 120 Pages
Global
From €2380EUR$2,500USD£2,042GBP
- Report
- August 2022
Global
From €943EUR$990USD£808GBP
- Report
- February 2021
Global
From €2818EUR$2,960USD£2,417GBP
- Clinical Trials
- March 2020
- 1115 Pages
Global
From €2380EUR$2,500USD£2,042GBP
- Drug Pipelines
- September 2020
- 385 Pages
Global
From €1904EUR$2,000USD£1,633GBP
- Report
- December 2022
- 111 Pages
Global
From €3500EUR$3,938USD£3,107GBP
- Report
- May 2022
- 89 Pages
Global
From €3500EUR$3,938USD£3,107GBP
- Report
- May 2022
- 270 Pages
Global
From €2380EUR$2,500USD£2,042GBP
- Report
- April 2019
- 47 Pages
Global
From €1713EUR$1,799USD£1,469GBP
- Clinical Trials
- February 2019
- 327 Pages
Global
From €2094EUR$2,199USD£1,796GBP
The Myocardial Infarction Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat and prevent heart diseases. Myocardial Infarction Drugs are used to treat acute myocardial infarction (AMI), also known as a heart attack. These drugs are used to reduce the risk of death and complications from AMI, such as heart failure, arrhythmias, and stroke. Commonly used Myocardial Infarction Drugs include anticoagulants, antiplatelet agents, beta-blockers, and statins. These drugs are used to reduce the risk of blood clots, reduce inflammation, and lower cholesterol levels.
Some companies in the Myocardial Infarction Drug market include Pfizer, Merck, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more
